Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $82.5 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. Companies worth $10 billion or more are generally described as “large-cap stocks,” and REGN perfectly fits that description, with its market cap exceeding this mar ...

Prosper Stars & Stripes, a long/short equity fund, recently released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter of 2025, Prosper Stars & Stripes achieved a net return of +9.8%. In comparison, its long/short equity hedge fund peer group, as indicated by the HFRX Equity Hedge (Total) Index (the “HFRX”), reported a total return of +3.8%. Additionally, the long-only small-cap Russell 2000 Index (the “Russell”) had a total return of +12.4%. Year to ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Uber has impressed the market in its post-pandemic years. Can it continue?Uber Technologies (UBER +2.50%) has been one of the most impressive turnaround stories in the stock market in recent years. The ridesharing giant went from a busted initial public offering (IPO) in 2019 to slogging through the pandemic.At one point, the transportation stock was trading down more than 50% from its IPO price. However, CEO Dara Khosrowshahi, who was brought in eight years ago to help repair the brand, has streamlined the ...

Joining us now, John Belton, portfolio manager for growth equities at Gabelli Funds. Okay. Where do you see it.What what were numbers there. 7100 7500 8,000. Pick a number. >> I'm not going to pick a number.That's that's too risky. I'm not going to do that in a public forum. But um I do think this this issue >> Well, you can give me any number.Just don't give me the [laughter] cake. >> Let's go let's go 7% higher from here. The long-term average.>> Okay, great. Yeah, that's bold. So, I mean, I do think this ...

Prosper Stars & Stripes, a long/short equity fund, recently released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter of 2025, Prosper Stars & Stripes achieved a net return of +9.8%. In comparison, its long/short equity hedge fund peer group, as indicated by the HFRX Equity Hedge (Total) Index (the “HFRX”), reported a total return of +3.8%. Additionally, the long-only small-cap Russell 2000 Index (the “Russell”) had a total return of +12.4%. Year to ...

I gave a buy rating to Similarweb ( SMWB ) previously, as the Q2 results were bullish, showing broad-based strength, better upmarket traction, and positive developments with monetizing its Gen-AI efforts. SWMB is scaling well with its Gen-AII'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in ...

Accessibility StatementSkip Navigation Comes as another milestone in the strategic partnership with Intellistake Deployment of First IntelliScope AI Agent Hub Closed beta testing has been underway internally TORONTO, Nov. 28, 2025 /PRNewswire/ - PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103)Â ("PowerBank" or the "Company"), today announces continued progress in its partnership with Intellistake Technologies Corp. (CSE: ISTK) ("Intellistake") as PowerBank is participating as a closed beta pa ...

Galway, Ireland-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients. Valued at $134.7 billion by market cap, the company's principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Companies worth $10 billion or more are generally described as ...